Novartis: Kisqali improves global survival

(CercleFinance.com) - Novartis announced on Monday that a Phase 3 clinical study showed a "statistically significant" improvement in overall survival in patients with advanced HR+/HER2- breast cancer treated with Kisqali.


The clinical trial that evaluated a combination of Kisqali and endocrinology-based therapy versus placebo, combined with endocrine therapy in women.

The overall survival rate is an indicator that is particularly monitored in clinical studies of cancer treatments.


Copyright (c) 2020 CercleFinance.com. All rights reserved.